JP2023501789A5 - - Google Patents

Info

Publication number
JP2023501789A5
JP2023501789A5 JP2022525877A JP2022525877A JP2023501789A5 JP 2023501789 A5 JP2023501789 A5 JP 2023501789A5 JP 2022525877 A JP2022525877 A JP 2022525877A JP 2022525877 A JP2022525877 A JP 2022525877A JP 2023501789 A5 JP2023501789 A5 JP 2023501789A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
amorphous form
further characterized
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022525877A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501789A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/059280 external-priority patent/WO2021092286A1/en
Publication of JP2023501789A publication Critical patent/JP2023501789A/ja
Publication of JP2023501789A5 publication Critical patent/JP2023501789A5/ja
Priority to JP2025171004A priority Critical patent/JP2026016449A/ja
Pending legal-status Critical Current

Links

JP2022525877A 2019-11-08 2020-11-06 補体成分C5a受容体の非晶質形態 Pending JP2023501789A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025171004A JP2026016449A (ja) 2019-11-08 2025-10-09 補体成分C5a受容体の非晶質形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962932644P 2019-11-08 2019-11-08
US62/932,644 2019-11-08
PCT/US2020/059280 WO2021092286A1 (en) 2019-11-08 2020-11-06 Amorphous form of a complement component c5a receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025171004A Division JP2026016449A (ja) 2019-11-08 2025-10-09 補体成分C5a受容体の非晶質形態

Publications (2)

Publication Number Publication Date
JP2023501789A JP2023501789A (ja) 2023-01-19
JP2023501789A5 true JP2023501789A5 (cg-RX-API-DMAC7.html) 2023-11-10

Family

ID=75846408

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525877A Pending JP2023501789A (ja) 2019-11-08 2020-11-06 補体成分C5a受容体の非晶質形態
JP2025171004A Pending JP2026016449A (ja) 2019-11-08 2025-10-09 補体成分C5a受容体の非晶質形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025171004A Pending JP2026016449A (ja) 2019-11-08 2025-10-09 補体成分C5a受容体の非晶質形態

Country Status (14)

Country Link
US (1) US11603356B2 (cg-RX-API-DMAC7.html)
EP (1) EP4054576A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023501789A (cg-RX-API-DMAC7.html)
KR (1) KR20220098754A (cg-RX-API-DMAC7.html)
CN (1) CN114641288A (cg-RX-API-DMAC7.html)
AU (1) AU2020378397A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022007489A2 (cg-RX-API-DMAC7.html)
CA (1) CA3155542A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001172A1 (cg-RX-API-DMAC7.html)
IL (1) IL292383A (cg-RX-API-DMAC7.html)
MX (1) MX2022005406A (cg-RX-API-DMAC7.html)
TW (1) TWI921314B (cg-RX-API-DMAC7.html)
WO (1) WO2021092286A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202305624B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020380367B2 (en) 2019-11-08 2026-06-04 Chemocentryx, Inc. Salt forms of a complement component C5a receptor
KR20220098754A (ko) 2019-11-08 2022-07-12 케모센트릭스, 인크. 보체 성분 C5a 수용체의 비정질 형태
WO2022078269A1 (zh) * 2020-10-16 2022-04-21 苏州科睿思制药有限公司 Avacopan的晶型及其制备方法和用途
WO2022263263A1 (en) 2021-06-16 2022-12-22 Sandoz Ag Crystalline form of avacopan
EP4137133A1 (en) 2021-08-19 2023-02-22 Sandoz AG Crystalline form of avacopan
WO2025227089A1 (en) 2024-04-26 2025-10-30 Amgen Inc. Solid state forms of (2r,3s)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-n-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide
US20260027049A1 (en) 2024-07-23 2026-01-29 Amgen Inc. Avacopan formulations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031548B (zh) 2004-09-27 2011-04-06 阿卡蒂亚药品公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备
JP5819730B2 (ja) 2008-12-22 2015-11-24 ケモセントリックス,インコーポレイティド C5aRアンタゴニスト
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
DK2585064T3 (en) 2010-06-24 2017-07-24 Chemocentryx Inc C5aR antagonists
JP6898229B6 (ja) * 2014-09-29 2021-07-28 ケモセントリックス,インコーポレイティド C5aRアンタゴニスト製造における方法及び中間体
KR20200109297A (ko) 2017-10-31 2020-09-22 케모센트릭스, 인크. 소변 sCD163의 C5aR 억제제 감소
JP2021527062A (ja) 2018-06-07 2021-10-11 ケモセントリックス,インコーポレイティド ANCA関連血管炎に対するc5aアンタゴニストの投薬及び効果
CN113164403A (zh) 2018-11-30 2021-07-23 凯莫森特里克斯股份有限公司 胶囊制剂
BR112021017756A2 (pt) 2019-03-11 2021-11-16 Inflarx Gmbh Piperidinila bicíclica fundida e compostos relacionados como moduladores do receptor c5a
AU2020378061A1 (en) 2019-11-08 2022-05-26 Chemocentryx, Inc. Free base crystalline form of a complement component C5a receptor
KR20220098754A (ko) 2019-11-08 2022-07-12 케모센트릭스, 인크. 보체 성분 C5a 수용체의 비정질 형태
AU2020380367B2 (en) 2019-11-08 2026-06-04 Chemocentryx, Inc. Salt forms of a complement component C5a receptor
WO2022078269A1 (zh) 2020-10-16 2022-04-21 苏州科睿思制药有限公司 Avacopan的晶型及其制备方法和用途

Similar Documents

Publication Publication Date Title
JP2022554019A5 (cg-RX-API-DMAC7.html)
HRP20171176T1 (hr) C5ar antagonisti
JP2008508885A5 (cg-RX-API-DMAC7.html)
TWI344957B (en) Chemical process and intermediates
TW202204335A (zh) Lnp023之結晶形式
JP2022510304A5 (cg-RX-API-DMAC7.html)
JP2011513485A5 (cg-RX-API-DMAC7.html)
JP2010280715A (ja) シナカルセト塩酸塩結晶フォームiの調製方法
US20190152794A1 (en) Layered double hydroxides
TW201016713A (en) Method for purification of adefovir dipivoxil
JP2020019813A5 (cg-RX-API-DMAC7.html)
CN108367267A (zh) 吸附材料粒子
JP2017210488A5 (cg-RX-API-DMAC7.html)
WO2018033149A1 (zh) 奥扎莫德的晶型及其制备方法
JP2021091629A (ja) D−アロース結晶及びその製造方法
TW202033508A (zh) 貝前列素-314d晶體及其製備方法
CN106904657A (zh) 尺寸可调的羟基氧化铁纳米粒子及其制备方法
CN110272724B (zh) 一种碳基高导热定形相变材料的制备方法
JP4538842B2 (ja) 新規ナテグリニド結晶
RU2022115355A (ru) АМОРФНАЯ ФОРМА КОМПОНЕНТА КОМПЛЕМЕНТА РЕЦЕПТОРА C5a
CN114671913A (zh) 一种神经激肽-1拮抗剂的晶型及其制备方法
JP2010139696A5 (cg-RX-API-DMAC7.html)
RU2009104346A (ru) Ксинафоатная соль замещенного 5-оксазол-2-ил-хинолинового соединения
TW202532080A (zh) 具有改良溶解度之新穎瓦莫洛龍(vamorolone)製劑
CN102070654B (zh) 一种头孢硫脒的制备方法